Related Experiment Video

Updated: Apr 26, 2026

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
06:04

Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae

Published on: February 24, 2023

3.1K

Community-acquired pneumonia caused by macrolide-resistant Mycoplasma pneumoniae in adults

Shigeo Hanada1, Miyuki Morozumi, Yui Takahashi

  • 1Department of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Japan.

Internal Medicine (Tokyo, Japan)
|August 5, 2014
PubMed

Insights

Macrolide-resistant Mycoplasma pneumoniae (MRMP) causes severe pneumonia in adults. Fluoroquinolones or tetracyclines are effective treatments when macrolides fail, highlighting the need for surveillance.

Area of Science:

  • Infectious Diseases
  • Pulmonology
  • Microbiology

Background:

  • Community-acquired pneumonia (CAP) can be caused by atypical pathogens like Mycoplasma pneumoniae.
  • Macrolide antibiotics are a common first-line treatment for M. pneumoniae infections.
  • Emerging antibiotic resistance poses a significant challenge to effective treatment strategies.

Observation:

  • A case study details an adult with severe community-acquired pneumonia due to macrolide-resistant Mycoplasma pneumoniae (MRMP).
  • The patient initially deteriorated with macrolide therapy but improved significantly after switching to fluoroquinolones.
  • A series of 14 M. pneumoniae pneumonia cases revealed 11 infections with MRMP.

Findings:

  • Of eight MRMP cases initially treated with macrolides, seven showed no improvement.
  • Successful treatment outcomes for MRMP were observed with fluoroquinolones or tetracyclines.
  • This underscores the clinical impact of macrolide resistance in M. pneumoniae.

Implications:

  • Current empirical treatment guidelines for M. pneumoniae may need revision in areas with high MRMP prevalence.
  • Nationwide surveillance for MRMP is crucial for understanding its epidemiology and guiding treatment.
  • Effective management of MRMP requires timely diagnosis and appropriate antibiotic selection, potentially including fluoroquinolones or tetracyclines.

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

14.6K

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
78
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
20
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.4K
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and...
202
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
84
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K